AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26414893 — intervention group
Group type: COMPARATOR
Intervention: Wait-list
Number of subjects: 90
Study 25622633 — intervention group
Group type: EXPERIMENTAL
Intervention: Compound digestive enzyme tablet (Bearse) plus 2 analog capsules of compound digestive enzyme thrice daily
Number of subjects: 203
Study 25622633 — intervention group
Group type: COMPARATOR
Intervention: Compound digestive enzyme capsule (Dages) plus 1 analog tablet of compound digestive enzyme thrice daily
Number of subjects: 203
Study 25622633 — intervention group
Group type: EXPERIMENTAL
Intervention: Compound digestive enzyme tablet (Bearse)
Number of subjects: 203
Study 25622633 — intervention group
Group type: COMPARATOR
Intervention: Compound digestive enzyme capsule (Dages)
Number of subjects: 203
Study 23246119 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical voriconazole therapy (1% voriconazole)
Number of subjects: 40
Study 23246119 — intervention group
Group type: COMPARATOR
Intervention: Intrastromal voriconazole (50 μg/0.1 ml)
Number of subjects: 40
Study 20973308 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed luer-lock access connectors
Number of subjects: 0
Study 18837860 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine (400-800 mg/day, twice daily)
Number of subjects: 59
Study 18837860 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 16909881 — intervention group
Group type: EXPERIMENTAL
Intervention: Microgravity environment during parabolic flight
Number of subjects: 8
Study 16909881 — intervention group
Group type: COMPARATOR
Intervention: Ground control sessions
Number of subjects: 8
Study 12482798 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon angioplasty alone (group 1)
Number of subjects: 54
Study 12482798 — intervention group
Group type: EXPERIMENTAL
Intervention: Stent placement (group 2)
Number of subjects: 54
Study 12482798 — intervention group
Group type: COMPARATOR
Intervention: Residual gradient > 10 mm Hg
Number of subjects: 54
Study 12482798 — intervention group
Group type: COMPARATOR
Intervention: Residual gradient ≤ 10 mm Hg
Number of subjects: 54
Study 10096260 — intervention group
Group type: EXPERIMENTAL
Intervention: R-verapamil (120 mg)
Number of subjects: 9
Study 10096260 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 7780619 — intervention group
Group type: EXPERIMENTAL
Intervention: rTPA
Number of subjects: 104
Study 7780619 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 104
Study 7780619 — intervention group
Group type: EXPERIMENTAL
Intervention: Large infarcts
Number of subjects: 104
Study 7780619 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 104
Study 2202889 — intervention group
Group type: EXPERIMENTAL
Intervention: 720-kcal liquid mixed meal (24% protein, 21% fat, 55% carbohydrate)
Number of subjects: 14
Study 497074 — intervention group
Group type: EXPERIMENTAL
Intervention: Extradural analgesia (EA) with 50 or 100 mg of etidocaine without adrenaline in the supine position
Number of subjects: 70
Study 497074 — intervention group
Group type: EXPERIMENTAL
Intervention: Extradural analgesia (EA) with 50 or 100 mg of etidocaine without adrenaline in the lateral position
Number of subjects: 70
Study 497074 — intervention group
Group type: COMPARATOR
Intervention: Control period before EA
Number of subjects: 70
Study 497074 — intervention group
Group type: EXPERIMENTAL
Intervention: Decrease in arterial pressure (AP)
Number of subjects: 70
Study 30049849 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressin V2 receptor antagonists
Number of subjects: 0
Study 30049849 — intervention group
Group type: EXPERIMENTAL
Intervention: Rigorous blood pressure control and various lifestyle and dietary changes
Number of subjects: 0
Study 30049849 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring and basic optimized kidney protective measures
Number of subjects: 0
Study 30049849 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease-modifying treatments (e.g., somatostatin analogs and other novel agents)
Number of subjects: 0
Study 27283107 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary catheter removal within 48 hours after operation
Number of subjects: 374
Study 27283107 — intervention group
Group type: COMPARATOR
Intervention: Urinary catheter removal 6 hours after epidural catheter removal
Number of subjects: 374
Study 25332317 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive low-salt diet education
Number of subjects: 245
Study 25332317 — intervention group
Group type: COMPARATOR
Intervention: Conventional low-salt diet education
Number of subjects: 245
Study 25332317 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 245
Study 21738002 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated impaired glucose tolerance (i-IGT)
Number of subjects: 1869
Study 21738002 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated impaired fasting glucose (i-IFG)
Number of subjects: 1869
Study 21738002 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined fasting and post-prandial hyperglycemia (IFG/IGT)
Number of subjects: 1869
Study 21738002 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects with 2 or more metabolic disorders
Number of subjects: 1869
Study 19949136 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin, 80 mg/d for 8 weeks
Number of subjects: 156
Study 19949136 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 156
Study 19034856 — intervention group
Group type: EXPERIMENTAL
Intervention: ATTENTIONER therapy
Number of subjects: 0
Study 15733716 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal hospital diet plus oral nutritional supplements
Number of subjects: 4023
Study 15733716 — intervention group
Group type: COMPARATOR
Intervention: Normal hospital diet
Number of subjects: 4023
Study 14571284 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine with honey (200 mg carbamazepine + 30 ml honey)
Number of subjects: 10
Study 14571284 — intervention group
Group type: COMPARATOR
Intervention: Carbamazepine with water (200 mg carbamazepine + water)
Number of subjects: 10
Study 10356595 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smokers
Number of subjects: 346
Study 10356595 — intervention group
Group type: COMPARATOR
Intervention: Non-smokers
Number of subjects: 346
Study 10356595 — intervention group
Group type: EXPERIMENTAL
Intervention: Under-reporters
Number of subjects: 346
Study 10356595 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intake assessment
Number of subjects: 346
Study 8618248 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended relief acetaminophen
Number of subjects: 10
Study 8618248 — intervention group
Group type: COMPARATOR
Intervention: Regular release acetaminophen
Number of subjects: 10
Study 2340539 — intervention group
Group type: COMPARATOR
Intervention: ORS‐90 (WHO ORS) with sodium 90 mmol/L and glucose 111 mmol/L, osmolality 311 mosm/kg
Number of subjects: 130
Study 2340539 — intervention group
Group type: EXPERIMENTAL
Intervention: ORS‐60 with sodium 60 mmol/L and glucose 90 mmol/L, osmolality 240 mosm/kg
Number of subjects: 130
Study 2340539 — intervention group
Group type: EXPERIMENTAL
Intervention: Both ORS groups
Number of subjects: 130
Study 7282615 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspartame (34 mg/kg body weight)
Number of subjects: 6
Study 7282615 — intervention group
Group type: COMPARATOR
Intervention: Sucrose (1 g/kg body weight)
Number of subjects: 6
Study 6143039 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic field therapy (PEMF)
Number of subjects: 29
Study 6143039 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 29
Study 6143039 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (after 8 weeks without treatment)
Number of subjects: 29
Study 31358436 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 14
Study 31358436 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 14
Study 31358436 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 28340044 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-0677
Number of subjects: 26
Study 28340044 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 27328752 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone/bupropion (NB) 32/360 mg
Number of subjects: 2043
Study 27328752 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2043
Study 24251424 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplement drinks served in a glass/beaker
Number of subjects: 45
Study 24251424 — intervention group
Group type: COMPARATOR
Intervention: Nutritional supplement drinks served via straw
Number of subjects: 45
Study 22568178 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects with carbohydrate disorders
Number of subjects: 112
Study 22568178 — intervention group
Group type: COMPARATOR
Intervention: Comparative group without cardiovascular diseases and carbohydrate disorders
Number of subjects: 112
Study 20200540 — intervention group
Group type: EXPERIMENTAL
Intervention: Multinutrient supplement providing increased protein and energy (P/E)
Number of subjects: 23
Study 20200540 — intervention group
Group type: COMPARATOR
Intervention: Energy supplementation alone (medium chain triglyceride oil, MCT)
Number of subjects: 23
Study 17638495 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive display rules (e.g., be enthusiastic and hide frustration)
Number of subjects: 0
Study 17638495 — intervention group
Group type: COMPARATOR
Intervention: Display autonomy
Number of subjects: 0
Study 17638495 — intervention group
Group type: EXPERIMENTAL
Intervention: Customer hostility during one of the calls
Number of subjects: 0
Study 15947510 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to related cues
Number of subjects: 3
Study 15947510 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to related and other cues followed by well-being therapy (WBT)
Number of subjects: 3
Study 15947510 — intervention group
Group type: EXPERIMENTAL
Intervention: Well-being therapy (WBT)
Number of subjects: 3
Study 12233989 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MTP)
Number of subjects: 48
Study 12233989 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 10102254 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss of 11.7% ± 2.8% at 8 weeks
Number of subjects: 25
Study 10102254 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss of 20.1% ± 7.0% at 48 weeks
Number of subjects: 25
Study 10102254 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss maintained at week 100
Number of subjects: 25
Study 10102254 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight gain of 7.4 ± 7.4 kg from weeks 48 to 100
Number of subjects: 25
Study 10102254 — intervention group
Group type: EXPERIMENTAL
Intervention: High-density lipoprotein cholesterol
Number of subjects: 25
Study 7597439 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel plus carboplatin (doses escalated from 300 to 450 mg/m2 for carboplatin and 125 to 175 mg/m2 for paclitaxel)
Number of subjects: 14
Study 2113764 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin (15 mg)
Number of subjects: 20
Study 2113764 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg, 3 times daily)
Number of subjects: 20
Study 288389 — intervention group
Group type: EXPERIMENTAL
Intervention: Factor VIII concentrate (30 units/kg)
Number of subjects: 4
Study 288389 — intervention group
Group type: EXPERIMENTAL
Intervention: Prothrombin-complex concentrate (Prothrombinex, 30 units of factor IX/kg)
Number of subjects: 4
Study 30584782 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (CT; multimodal therapy plus aerobic training)
Number of subjects: 126
Study 30584782 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal therapy (MT)
Number of subjects: 126
Study 30584782 — intervention group
Group type: COMPARATOR
Intervention: Aerobic training (AT)
Number of subjects: 126
Study 28121280 — intervention group
Group type: EXPERIMENTAL
Intervention: Survey and education pamphlet (intervention group)
Number of subjects: 237
Study 28121280 — intervention group
Group type: COMPARATOR
Intervention: Survey only (control group)
Number of subjects: 237
Study 27490162 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium Respimat 5 µg
Number of subjects: 2356
Study 27490162 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium Respimat 2.5 µg
Number of subjects: 2356
Study 27490162 — intervention group
Group type: COMPARATOR
Intervention: HandiHaler 18 µg
Number of subjects: 2356
Study 23748157 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care (POC) testing
Number of subjects: 811
Study 23748157 — intervention group
Group type: COMPARATOR
Intervention: Laboratory testing (Control)
Number of subjects: 811
Study 22155531 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-regulatory intervention (SRI) focused on self-monitoring of spontaneous physical activity (SPA)
Number of subjects: 72
Study 22155531 — intervention group
Group type: COMPARATOR
Intervention: Weight loss intervention without self-regulatory behavioral strategy
Number of subjects: 72
Study 19197174 — intervention group
Group type: EXPERIMENTAL
Intervention: Couple-based interventions that educate both partners about the woman's diagnosis and treatments, promote mutual coping and support, and include sexual therapy techniques.
Number of subjects: 12
Study 19197174 — intervention group
Group type: EXPERIMENTAL
Intervention: Couple-focused interventions
Number of subjects: 12
Study 19197174 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions including sexual therapy techniques
Number of subjects: 12
Study 19197174 — intervention group
Group type: EXPERIMENTAL
Intervention: Future interventions should include measures of body image, sexual satisfaction, and sexual dysfunction.
Number of subjects: 12
Study 17203016 — intervention group
Group type: EXPERIMENTAL
Intervention: Vagus nerve stimulation (VNS) therapy
Number of subjects: 9
Study 17203016 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute VNS
Number of subjects: 9
Study 17203016 — intervention group
Group type: EXPERIMENTAL
Intervention: VNS therapy
Number of subjects: 9
Study 15206991 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbogrel 150 mg
Number of subjects: 48
Study 15206991 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbogrel 50 mg, 100 mg, 150 mg
Number of subjects: 48
Study 15206991 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 15206991 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid 330 mg once-a-day
Number of subjects: 48
Study 11143737 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib 50 mg
Number of subjects: 6
Study 11143737 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 11143737 — intervention group
Group type: COMPARATOR
Intervention: Naproxen sodium 550 mg or ibuprofen 400 mg
Number of subjects: 6
Study 9360028 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg/day ASA at Time 2 (7h to 9h after awakening)
Number of subjects: 91
Study 9360028 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg/day ASA at Time 3 (within 2h of bedtime)
Number of subjects: 91
Study 9360028 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg/day ASA at Time 2 (7h to 9h after awakening)
Number of subjects: 91
Study 9360028 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg/day ASA for hypertensive patients at Time 2 (7h to 9h after awakening)
Number of subjects: 91
Study 9360028 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg/day ASA for hypertensive patients at Time 3 (within 2h of bedtime)
Number of subjects: 91
Study 8473961 — intervention group
Group type: EXPERIMENTAL
Intervention: Coached on symptoms of schizophrenia
Number of subjects: 72
Study 8473961 — intervention group
Group type: EXPERIMENTAL
Intervention: Coached on strategies for the detection of fakers
Number of subjects: 72
Study 8473961 — intervention group
Group type: EXPERIMENTAL
Intervention: Coached on both symptoms and strategies
Number of subjects: 72
Study 8473961 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncoached
Number of subjects: 72
Study 8473961 — intervention group
Group type: COMPARATOR
Intervention: Honest condition
Number of subjects: 72
Study 8473961 — intervention group
Group type: COMPARATOR
Intervention: Schizophrenic inpatients
Number of subjects: 72
Study 3009050 — intervention group
Group type: EXPERIMENTAL
Intervention: Abrupt withdrawal of beta-blockers (group 1)
Number of subjects: 326
Study 3009050 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (group 1)
Number of subjects: 326
Study 3009050 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation of beta-blockade therapy (group 4)
Number of subjects: 326
Study 3009050 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal of beta-blockade (group 3)
Number of subjects: 326
Study 29126270 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal Strength Training (MST)
Number of subjects: 23
Study 29126270 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 23
Study 28478138 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention Bias Modification Training (ABMT)
Number of subjects: 29
Study 28478138 — intervention group
Group type: COMPARATOR
Intervention: Placebo Training (PT)
Number of subjects: 29
Study 25028177 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter Ablation (CA)
Number of subjects: 146
Study 25028177 — intervention group
Group type: COMPARATOR
Intervention: Antiarrhythmic Drug Therapy (ADT)
Number of subjects: 146
Study 23411788 — intervention group
Group type: EXPERIMENTAL
Intervention: High-efficiency postdilution online hemodiafiltration (OL-HDF)
Number of subjects: 906
Study 23411788 — intervention group
Group type: COMPARATOR
Intervention: Conventional hemodialysis
Number of subjects: 906
Study 21667142 — intervention group
Group type: EXPERIMENTAL
Intervention: Communities That Care (CTC) intervention in 12 communities
Number of subjects: 24
Study 21667142 — intervention group
Group type: COMPARATOR
Intervention: Control communities (12 communities)
Number of subjects: 24
Study 18486752 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative testing (experimental group)
Number of subjects: 114
Study 18486752 — intervention group
Group type: COMPARATOR
Intervention: Individualistic testing (control group)
Number of subjects: 114
Study 16516074 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab-coated stents (group I)
Number of subjects: 96
Study 16516074 — intervention group
Group type: COMPARATOR
Intervention: Bare metal control stents (group II)
Number of subjects: 96
Study 12937228 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (50 mg daily)
Number of subjects: 97
Study 12937228 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine (5 mg daily)
Number of subjects: 97
Study 11201622 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric muscle strength in knee extensors and flexors
Number of subjects: 144
Study 11201622 — intervention group
Group type: EXPERIMENTAL
Intervention: Isokinetic muscle strength at 60 degrees/s and 180 degrees/s in knee extensors and flexors
Number of subjects: 144
Study 11201622 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic and static endurance of knee extensors
Number of subjects: 144
Study 11201622 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric strength in ankle plantar and dorsiflexor muscles
Number of subjects: 144
Study 11201622 — intervention group
Group type: EXPERIMENTAL
Intervention: Isokinetic ankle plantar flexion strength at 60 degrees/s with and without prior eccentric contraction
Number of subjects: 144
Study 11201622 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand-grip strength evaluated with a dynamometer
Number of subjects: 144
Study 11201622 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking velocity and number of heel-rises
Number of subjects: 144
Study 11201622 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle biopsies from vastus lateralis muscle for histochemical and enzymatic analyses
Number of subjects: 144
Study 9180836 — intervention group
Group type: EXPERIMENTAL
Intervention: Ifosfamide 15 g/m2/cycle
Number of subjects: 10
Study 9180836 — intervention group
Group type: EXPERIMENTAL
Intervention: Ifosfamide 3 g/m2 during 5 days
Number of subjects: 10
Study 1587761 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-a-day radiation therapy (hyperfractionation) delivering 120 cGy per fraction, two fractions a day for a total of 6000 cGy in 50 fractions over 5 weeks
Number of subjects: 30
Study 1587761 — intervention group
Group type: COMPARATOR
Intervention: Conventional fractionation delivering 200 cGy per fraction for a total of 5000 cGy in 25 fractions over 5 weeks
Number of subjects: 30
Study 3929934 — intervention group
Group type: EXPERIMENTAL
Intervention: Paediatric endoscopic forceps biopsy
Number of subjects: 40
Study 3929934 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard endoscopic forceps biopsy
Number of subjects: 40
Study 3929934 — intervention group
Group type: EXPERIMENTAL
Intervention: Duodenal capsule biopsy
Number of subjects: 40
Study 3929934 — intervention group
Group type: EXPERIMENTAL
Intervention: Jejunal capsule biopsy
Number of subjects: 40
Study 31667062 — intervention group
Group type: EXPERIMENTAL
Intervention: Saracatinib 125 mg/day for 28 days
Number of subjects: 12
Study 31667062 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 29925849 — intervention group
Group type: EXPERIMENTAL
Intervention: Spatial bisection task
Number of subjects: 23
Study 29925849 — intervention group
Group type: COMPARATOR
Intervention: Minimum audible angle (MAA) task
Number of subjects: 23
Study 29925849 — intervention group
Group type: COMPARATOR
Intervention: Temporal bisection task
Number of subjects: 23
Study 27755159 — intervention group
Group type: EXPERIMENTAL
Intervention: Peony-Glycyrrhiza Decoction (PGD) 45 g/d for 16 weeks
Number of subjects: 99
Study 27755159 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study 24148194 — intervention group
Group type: EXPERIMENTAL
Intervention: GH (30 ng × kg(‐1) × min(‐1))
Number of subjects: 8
Study 24148194 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting (36 h)
Number of subjects: 8
Study 24148194 — intervention group
Group type: EXPERIMENTAL
Intervention: GH
Number of subjects: 8
Study 24148194 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting
Number of subjects: 8
Study 24148194 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 8